BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29562176)

  • 1. KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer.
    Knight JF; Sung VYC; Kuzmin E; Couzens AL; de Verteuil DA; Ratcliffe CDH; Coelho PP; Johnson RM; Samavarchi-Tehrani P; Gruosso T; Smith HW; Lee W; Saleh SM; Zuo D; Zhao H; Guiot MC; Davis RR; Gregg JP; Moraes C; Gingras AC; Park M
    Cell Rep; 2018 Mar; 22(12):3191-3205. PubMed ID: 29562176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.
    Liu J; Ye L; Li Q; Wu X; Wang B; Ouyang Y; Yuan Z; Li J; Lin C
    J Pathol; 2018 Jan; 244(1):71-83. PubMed ID: 28991374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
    Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
    Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTPN14 forms a complex with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function.
    Wilson KE; Li YW; Yang N; Shen H; Orillion AR; Zhang J
    J Biol Chem; 2014 Aug; 289(34):23693-700. PubMed ID: 25023289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low KIBRA Expression Is Associated with Poor Prognosis in Patients with Triple-Negative Breast Cancer.
    Kim SW; Chu J; Do SI; Na K
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441043
    [No Abstract]   [Full Text] [Related]  

  • 7. Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression.
    Guo L; Zheng J; Zhang J; Wang H; Shao G; Teng L
    Oncol Rep; 2016 Aug; 36(2):729-36. PubMed ID: 27373987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolutionary and molecular facts link the WWC protein family to Hippo signaling.
    Wennmann DO; Schmitz J; Wehr MC; Krahn MP; Koschmal N; Gromnitza S; Schulze U; Weide T; Chekuri A; Skryabin BV; Gerke V; Pavenstädt H; Duning K; Kremerskothen J
    Mol Biol Evol; 2014 Jul; 31(7):1710-23. PubMed ID: 24682284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
    Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
    Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CC chemokine receptor 7 promotes triple-negative breast cancer growth and metastasis.
    Wu J; Li L; Liu J; Wang Y; Wang Z; Wang Y; Liu W; Zhou Z; Chen C; Liu R; Yang R
    Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):835-842. PubMed ID: 30032244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition.
    Diepenbruck M; Waldmeier L; Ivanek R; Berninger P; Arnold P; van Nimwegen E; Christofori G
    J Cell Sci; 2014 Apr; 127(Pt 7):1523-36. PubMed ID: 24554433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low expression of WWC1, a tumor suppressor gene, is associated with aggressive breast cancer and poor survival outcome.
    Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Tiirikainen M; Yu H
    FEBS Open Bio; 2019 Jul; 9(7):1270-1280. PubMed ID: 31102318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
    Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
    Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRA.
    Schelleckes K; Schmitz B; Lenders M; Mewes M; Brand SM; Brand E
    Sci Rep; 2018 Mar; 8(1):4230. PubMed ID: 29523820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization.
    Chen W; Bai Y; Patel C; Geng F
    Biochem Biophys Res Commun; 2019 Dec; 520(2):263-268. PubMed ID: 31590917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
    Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
    Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
    Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
    Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
    Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.